APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peptide Vaccine for Tumor

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Peptide Vaccine for Tumor Market Outlook and Growth Opportunities 2026

27 December 2025192 pages

Choose your research edition.

Industry ResearchPeptide Vaccine for Tumor Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide Vaccine for Tumor Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Peptide Vaccine for Tumor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide Vaccine for Tumor Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide Vaccine for Tumor Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Peptide Vaccine for Tumor market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Peptide Vaccine for Tumor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Peptide Vaccine for Tumor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Peptide Vaccine for Tumor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Peptide Vaccine for Tumor market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Peptide Vaccine for Tumor market include AmbioPharm, Ultimovacs, Sellas Life Sciences, OncoPep, Marker Therapeutics, Inc., Immatics, Anergis, Almac and ACT, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Peptide Vaccine for Tumor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Peptide Vaccine for Tumor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Peptide Vaccine for Tumor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Peptide Vaccine for Tumor market size, projected growth trends, production technologies, key applications, and end-use industries.

Peptide Vaccine for Tumor Segment by Company

AmbioPharm

Ultimovacs

Sellas Life Sciences

OncoPep

Marker Therapeutics, Inc.

Immatics

Anergis

Almac

ACT

Peptide Vaccine for Tumor Segment by Type

Recombinant Polypeptide Vaccine

Synthetic Polypeptide Vaccines

Others

Peptide Vaccine for Tumor Segment by Application

Infectious Disease Prevention

Cancer Immunotherapy

Others

Peptide Vaccine for Tumor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Peptide Vaccine for Tumor status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Peptide Vaccine for Tumor market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Peptide Vaccine for Tumor significant trends, drivers, influence factors in global and regions.

6. To analyze Peptide Vaccine for Tumor competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Vaccine for Tumor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide Vaccine for Tumor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Vaccine for Tumor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Peptide Vaccine for Tumor market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Peptide Vaccine for Tumor industry.

Chapter 3: Detailed analysis of Peptide Vaccine for Tumor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Peptide Vaccine for Tumor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Peptide Vaccine for Tumor in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Peptide Vaccine for Tumor Industry Trends Table 2. Peptide Vaccine for Tumor Industry Drivers Table 3. Peptide Vaccine for Tumor Industry Opportunities and Challenges Table 4. Peptide Vaccine for Tumor Industry Restraints Table 5. Global Peptide Vaccine for Tumor Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Peptide Vaccine for Tumor Revenue Share by Company (2021-2026) Table 7. Global Peptide Vaccine for Tumor Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Peptide Vaccine for Tumor Sales Volume Share by Company (2021-2026) Table 9. Global Peptide Vaccine for Tumor Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Peptide Vaccine for Tumor Company Ranking, (2024-2026) & (USD Million) Table 11. Global Peptide Vaccine for Tumor Key Company Manufacturing Base & Headquarters Table 12. Global Peptide Vaccine for Tumor Company, Product Type & Application Table 13. Global Peptide Vaccine for Tumor Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Peptide Vaccine for Tumor by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Recombinant Polypeptide Vaccine Table 18. Significant Companies of Synthetic Polypeptide Vaccines Table 19. Significant Companies of Others Table 20. Global Peptide Vaccine for Tumor Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Peptide Vaccine for Tumor Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Peptide Vaccine for Tumor Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Peptide Vaccine for Tumor Sales Volume Share by Type (2021-2026) Table 24. Global Peptide Vaccine for Tumor Sales Volume Share by Type (2027-2032) Table 25. Global Peptide Vaccine for Tumor Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Peptide Vaccine for Tumor Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Peptide Vaccine for Tumor Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Peptide Vaccine for Tumor Sales Value Share by Type (2021-2026) Table 29. Global Peptide Vaccine for Tumor Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Infectious Disease Prevention Table 31. Significant Companies of Cancer Immunotherapy Table 32. Significant Companies of Others Table 33. Global Peptide Vaccine for Tumor Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Peptide Vaccine for Tumor Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Peptide Vaccine for Tumor Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Peptide Vaccine for Tumor Sales Volume Share by Application (2021-2026) Table 37. Global Peptide Vaccine for Tumor Sales Volume Share by Application (2027-2032) Table 38. Global Peptide Vaccine for Tumor Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Peptide Vaccine for Tumor Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Peptide Vaccine for Tumor Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Peptide Vaccine for Tumor Sales Value Share by Application (2021-2026) Table 42. Global Peptide Vaccine for Tumor Sales Value Share by Application (2027-2032) Table 43. Global Peptide Vaccine for Tumor Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Peptide Vaccine for Tumor Sales by Region (2021-2026) & (K Units) Table 45. Global Peptide Vaccine for Tumor Sales Market Share by Region (2021-2026) Table 46. Global Peptide Vaccine for Tumor Sales by Region (2027-2032) & (K Units) Table 47. Global Peptide Vaccine for Tumor Sales Market Share by Region (2027-2032) Table 48. Global Peptide Vaccine for Tumor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Peptide Vaccine for Tumor Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Peptide Vaccine for Tumor Sales Value Share by Region (2021-2026) Table 51. Global Peptide Vaccine for Tumor Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Peptide Vaccine for Tumor Sales Value Share by Region (2027-2032) Table 53. Global Peptide Vaccine for Tumor Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Peptide Vaccine for Tumor Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Peptide Vaccine for Tumor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Peptide Vaccine for Tumor Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Peptide Vaccine for Tumor Sales by Country (2021-2026) & (K Units) Table 58. Global Peptide Vaccine for Tumor Sales Market Share by Country (2021-2026) Table 59. Global Peptide Vaccine for Tumor Sales by Country (2027-2032) & (K Units) Table 60. Global Peptide Vaccine for Tumor Sales Market Share by Country (2027-2032) Table 61. Global Peptide Vaccine for Tumor Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Peptide Vaccine for Tumor Sales Value Market Share by Country (2021-2026) Table 63. Global Peptide Vaccine for Tumor Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Peptide Vaccine for Tumor Sales Value Market Share by Country (2027-2032) Table 65. AmbioPharm Company Information Table 66. AmbioPharm Business Overview Table 67. AmbioPharm Peptide Vaccine for Tumor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. AmbioPharm Peptide Vaccine for Tumor Product Portfolio Table 69. AmbioPharm Recent Development Table 70. Ultimovacs Company Information Table 71. Ultimovacs Business Overview Table 72. Ultimovacs Peptide Vaccine for Tumor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Ultimovacs Peptide Vaccine for Tumor Product Portfolio Table 74. Ultimovacs Recent Development Table 75. Sellas Life Sciences Company Information Table 76. Sellas Life Sciences Business Overview Table 77. Sellas Life Sciences Peptide Vaccine for Tumor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Sellas Life Sciences Peptide Vaccine for Tumor Product Portfolio Table 79. Sellas Life Sciences Recent Development Table 80. OncoPep Company Information Table 81. OncoPep Business Overview Table 82. OncoPep Peptide Vaccine for Tumor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. OncoPep Peptide Vaccine for Tumor Product Portfolio Table 84. OncoPep Recent Development Table 85. Marker Therapeutics, Inc. Company Information Table 86. Marker Therapeutics, Inc. Business Overview Table 87. Marker Therapeutics, Inc. Peptide Vaccine for Tumor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Marker Therapeutics, Inc. Peptide Vaccine for Tumor Product Portfolio Table 89. Marker Therapeutics, Inc. Recent Development Table 90. Immatics Company Information Table 91. Immatics Business Overview Table 92. Immatics Peptide Vaccine for Tumor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Immatics Peptide Vaccine for Tumor Product Portfolio Table 94. Immatics Recent Development Table 95. Anergis Company Information Table 96. Anergis Business Overview Table 97. Anergis Peptide Vaccine for Tumor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Anergis Peptide Vaccine for Tumor Product Portfolio Table 99. Anergis Recent Development Table 100. Almac Company Information Table 101. Almac Business Overview Table 102. Almac Peptide Vaccine for Tumor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Almac Peptide Vaccine for Tumor Product Portfolio Table 104. Almac Recent Development Table 105. ACT Company Information Table 106. ACT Business Overview Table 107. ACT Peptide Vaccine for Tumor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. ACT Peptide Vaccine for Tumor Product Portfolio Table 109. ACT Recent Development Table 110. Key Raw Materials Table 111. Raw Materials Key Suppliers Table 112. Peptide Vaccine for Tumor Distributors List Table 113. Peptide Vaccine for Tumor Customers List Table 114. Research Programs/Design for This Report Table 115. Authors List of This Report Table 116. Secondary Sources Table 117. Primary Sources List of Figures Figure 1. Peptide Vaccine for Tumor Product Image Figure 2. Global Peptide Vaccine for Tumor Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide Vaccine for Tumor Sales Value (2021-2032) & (US$ Million) Figure 4. Global Peptide Vaccine for Tumor Sales (2021-2032) & (K Units) Figure 5. Global Peptide Vaccine for Tumor Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Peptide Vaccine for Tumor Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Recombinant Polypeptide Vaccine Image Figure 10. Synthetic Polypeptide Vaccines Image Figure 11. Others Image Figure 12. Global Peptide Vaccine for Tumor Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Peptide Vaccine for Tumor Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Peptide Vaccine for Tumor Sales Volume Share by Type (2021-2032) Figure 15. Global Peptide Vaccine for Tumor Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Peptide Vaccine for Tumor Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Peptide Vaccine for Tumor Sales Value Share by Type (2021-2032) Figure 18. Infectious Disease Prevention Image Figure 19. Cancer Immunotherapy Image Figure 20. Others Image Figure 21. Global Peptide Vaccine for Tumor Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Peptide Vaccine for Tumor Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Peptide Vaccine for Tumor Sales Volume Share by Application (2021-2032) Figure 24. Global Peptide Vaccine for Tumor Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Peptide Vaccine for Tumor Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Peptide Vaccine for Tumor Sales Value Share by Application (2021-2032) Figure 27. Global Peptide Vaccine for Tumor Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Peptide Vaccine for Tumor Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Peptide Vaccine for Tumor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Peptide Vaccine for Tumor Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Peptide Vaccine for Tumor Sales Value (2021-2032) & (US$ Million) Figure 32. North America Peptide Vaccine for Tumor Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Peptide Vaccine for Tumor Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Peptide Vaccine for Tumor Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Peptide Vaccine for Tumor Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Peptide Vaccine for Tumor Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Peptide Vaccine for Tumor Sales Value (2021-2032) & (US$ Million) Figure 38. South America Peptide Vaccine for Tumor Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Peptide Vaccine for Tumor Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Peptide Vaccine for Tumor Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Peptide Vaccine for Tumor Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Peptide Vaccine for Tumor Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Recombinant Polypeptide Vaccine
  • Synthetic Polypeptide Vaccines
  • Others
Applications
  • Infectious Disease Prevention
  • Cancer Immunotherapy
  • Others
Companies covered
  • AmbioPharm
  • Ultimovacs
  • Sellas Life Sciences
  • OncoPep
  • Marker Therapeutics, Inc.
  • Immatics
  • Anergis
  • Almac
  • ACT

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Peptide Vaccine for Tumor Sales Value (2021-2032)
  4. 1.2.2 Global Peptide Vaccine for Tumor Sales Volume (2021-2032)
  5. 1.2.3 Global Peptide Vaccine for Tumor Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Peptide Vaccine for Tumor Market Dynamics
  1. 2.1 Peptide Vaccine for Tumor Industry Trends
  2. 2.2 Peptide Vaccine for Tumor Industry Drivers
  3. 2.3 Peptide Vaccine for Tumor Industry Opportunities and Challenges
  4. 2.4 Peptide Vaccine for Tumor Industry Restraints
3 Peptide Vaccine for Tumor Market by Company
  1. 3.1 Global Peptide Vaccine for Tumor Company Revenue Ranking in 2025
  2. 3.2 Global Peptide Vaccine for Tumor Revenue by Company (2021-2026)
  3. 3.3 Global Peptide Vaccine for Tumor Sales Volume by Company (2021-2026)
  4. 3.4 Global Peptide Vaccine for Tumor Average Price by Company (2021-2026)
  5. 3.5 Global Peptide Vaccine for Tumor Company Ranking (2024-2026)
  6. 3.6 Global Peptide Vaccine for Tumor Company Manufacturing Base and Headquarters
  7. 3.7 Global Peptide Vaccine for Tumor Company Product Type and Application
  8. 3.8 Global Peptide Vaccine for Tumor Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Peptide Vaccine for Tumor Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Peptide Vaccine for Tumor Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Peptide Vaccine for Tumor Market by Type
  1. 4.1 Peptide Vaccine for Tumor Type Introduction
  2. 4.1.1 Recombinant Polypeptide Vaccine
  3. 4.1.2 Synthetic Polypeptide Vaccines
  4. 4.1.3 Others
  5. 4.2 Global Peptide Vaccine for Tumor Sales Volume by Type
  6. 4.2.1 Global Peptide Vaccine for Tumor Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Peptide Vaccine for Tumor Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Peptide Vaccine for Tumor Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Peptide Vaccine for Tumor Sales Value by Type
  10. 4.3.1 Global Peptide Vaccine for Tumor Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Peptide Vaccine for Tumor Sales Value by Type (2021-2032)
  12. 4.3.3 Global Peptide Vaccine for Tumor Sales Value Share by Type (2021-2032)
5 Peptide Vaccine for Tumor Market by Application
  1. 5.1 Peptide Vaccine for Tumor Application Introduction
  2. 5.1.1 Infectious Disease Prevention
  3. 5.1.2 Cancer Immunotherapy
  4. 5.1.3 Others
  5. 5.2 Global Peptide Vaccine for Tumor Sales Volume by Application
  6. 5.2.1 Global Peptide Vaccine for Tumor Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Peptide Vaccine for Tumor Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Peptide Vaccine for Tumor Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Peptide Vaccine for Tumor Sales Value by Application
  10. 5.3.1 Global Peptide Vaccine for Tumor Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Peptide Vaccine for Tumor Sales Value by Application (2021-2032)
  12. 5.3.3 Global Peptide Vaccine for Tumor Sales Value Share by Application (2021-2032)
6 Peptide Vaccine for Tumor Regional Sales and Value Analysis
  1. 6.1 Global Peptide Vaccine for Tumor Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Peptide Vaccine for Tumor Sales by Region (2021-2032)
  3. 6.2.1 Global Peptide Vaccine for Tumor Sales by Region: 2021-2026
  4. 6.2.2 Global Peptide Vaccine for Tumor Sales by Region (2027-2032)
  5. 6.3 Global Peptide Vaccine for Tumor Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Peptide Vaccine for Tumor Sales Value by Region (2021-2032)
  7. 6.4.1 Global Peptide Vaccine for Tumor Sales Value by Region: 2021-2026
  8. 6.4.2 Global Peptide Vaccine for Tumor Sales Value by Region (2027-2032)
  9. 6.5 Global Peptide Vaccine for Tumor Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Peptide Vaccine for Tumor Sales Value (2021-2032)
  12. 6.6.2 North America Peptide Vaccine for Tumor Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Peptide Vaccine for Tumor Sales Value (2021-2032)
  15. 6.7.2 Europe Peptide Vaccine for Tumor Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Peptide Vaccine for Tumor Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Peptide Vaccine for Tumor Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Peptide Vaccine for Tumor Sales Value (2021-2032)
  21. 6.9.2 South America Peptide Vaccine for Tumor Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Peptide Vaccine for Tumor Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Peptide Vaccine for Tumor Sales Value Share by Country, 2025 VS 2032
7 Peptide Vaccine for Tumor Country-level Sales and Value Analysis
  1. 7.1 Global Peptide Vaccine for Tumor Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Peptide Vaccine for Tumor Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Peptide Vaccine for Tumor Sales by Country (2021-2032)
  4. 7.3.1 Global Peptide Vaccine for Tumor Sales by Country (2021-2026)
  5. 7.3.2 Global Peptide Vaccine for Tumor Sales by Country (2027-2032)
  6. 7.4 Global Peptide Vaccine for Tumor Sales Value by Country (2021-2032)
  7. 7.4.1 Global Peptide Vaccine for Tumor Sales Value by Country (2021-2026)
  8. 7.4.2 Global Peptide Vaccine for Tumor Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Peptide Vaccine for Tumor Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Peptide Vaccine for Tumor Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Peptide Vaccine for Tumor Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AmbioPharm
  2. 8.1.1 AmbioPharm Company Information
  3. 8.1.2 AmbioPharm Business Overview
  4. 8.1.3 AmbioPharm Peptide Vaccine for Tumor Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 AmbioPharm Peptide Vaccine for Tumor Product Portfolio
  6. 8.1.5 AmbioPharm Recent Developments
  7. 8.2 Ultimovacs
  8. 8.2.1 Ultimovacs Company Information
  9. 8.2.2 Ultimovacs Business Overview
  10. 8.2.3 Ultimovacs Peptide Vaccine for Tumor Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Ultimovacs Peptide Vaccine for Tumor Product Portfolio
  12. 8.2.5 Ultimovacs Recent Developments
  13. 8.3 Sellas Life Sciences
  14. 8.3.1 Sellas Life Sciences Company Information
  15. 8.3.2 Sellas Life Sciences Business Overview
  16. 8.3.3 Sellas Life Sciences Peptide Vaccine for Tumor Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sellas Life Sciences Peptide Vaccine for Tumor Product Portfolio
  18. 8.3.5 Sellas Life Sciences Recent Developments
  19. 8.4 OncoPep
  20. 8.4.1 OncoPep Company Information
  21. 8.4.2 OncoPep Business Overview
  22. 8.4.3 OncoPep Peptide Vaccine for Tumor Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 OncoPep Peptide Vaccine for Tumor Product Portfolio
  24. 8.4.5 OncoPep Recent Developments
  25. 8.5 Marker Therapeutics, Inc.
  26. 8.5.1 Marker Therapeutics, Inc. Company Information
  27. 8.5.2 Marker Therapeutics, Inc. Business Overview
  28. 8.5.3 Marker Therapeutics, Inc. Peptide Vaccine for Tumor Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Marker Therapeutics, Inc. Peptide Vaccine for Tumor Product Portfolio
  30. 8.5.5 Marker Therapeutics, Inc. Recent Developments
  31. 8.6 Immatics
  32. 8.6.1 Immatics Company Information
  33. 8.6.2 Immatics Business Overview
  34. 8.6.3 Immatics Peptide Vaccine for Tumor Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Immatics Peptide Vaccine for Tumor Product Portfolio
  36. 8.6.5 Immatics Recent Developments
  37. 8.7 Anergis
  38. 8.7.1 Anergis Company Information
  39. 8.7.2 Anergis Business Overview
  40. 8.7.3 Anergis Peptide Vaccine for Tumor Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Anergis Peptide Vaccine for Tumor Product Portfolio
  42. 8.7.5 Anergis Recent Developments
  43. 8.8 Almac
  44. 8.8.1 Almac Company Information
  45. 8.8.2 Almac Business Overview
  46. 8.8.3 Almac Peptide Vaccine for Tumor Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Almac Peptide Vaccine for Tumor Product Portfolio
  48. 8.8.5 Almac Recent Developments
  49. 8.9 ACT
  50. 8.9.1 ACT Company Information
  51. 8.9.2 ACT Business Overview
  52. 8.9.3 ACT Peptide Vaccine for Tumor Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 ACT Peptide Vaccine for Tumor Product Portfolio
  54. 8.9.5 ACT Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Peptide Vaccine for Tumor Value Chain Analysis
  2. 9.1.1 Peptide Vaccine for Tumor Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Peptide Vaccine for Tumor Sales Mode & Process
  6. 9.2 Peptide Vaccine for Tumor Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Peptide Vaccine for Tumor Distributors
  9. 9.2.3 Peptide Vaccine for Tumor Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst